Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Patients with relapsed or refractory large B-cell lymphomas (rrLBCL) can achieve long-term remission after CD19 chimeric antigen receptor T-cell therapy (CART19). However, more than half of recipients will experience treatment failure. Thus, approaches are needed to identify high-risk patients who m...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherng, Hua-Jay J., Sun, Ryan, Sugg, Bryant, Irwin, Russell, Yang, Haopeng, Le, Cao Cuong, Deng, Qing, Fayad, Luis, Fowler, Nathan H., Parmar, Simrit, Steiner, Raphael, Hagemeister, Fredrick, Nair, Ranjit, Lee, Hun Ju, Rodriguez, Maria, Samaniego, Felipe, Iyer, Swaminathan P., Flowers, Christopher R., Wang, Linghua, Nastoupil, Loretta J., Neelapu, Sattva S., Ahmed, Sairah, Strati, Paolo, Green, Michael R., Westin, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353148/
https://www.ncbi.nlm.nih.gov/pubmed/35512184
http://dx.doi.org/10.1182/blood.2022015601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353148/
https://www.ncbi.nlm.nih.gov/pubmed/35512184
http://dx.doi.org/10.1182/blood.2022015601

Ejemplares similares